K. Peter Hirth
About
In The Last Decade
K. Peter Hirth
13 papers receiving 2.2k citations
Hit Papers
Peers
Comparison fields: 5 of 96
- Molecular Biology 1.3k
- Pulmonary and Respiratory Medicine 679
- Cancer Research 520
- Oncology 518
- Surgery 372
Countries citing papers authored by K. Peter Hirth
This map shows the geographic impact of K. Peter Hirth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K. Peter Hirth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K. Peter Hirth more than expected).
Fields of papers citing papers by K. Peter Hirth
This network shows the impact of papers produced by K. Peter Hirth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K. Peter Hirth. The network helps show where K. Peter Hirth may publish in the future.
Co-authorship network of co-authors of K. Peter Hirth
This figure shows the co-authorship network connecting the top 25 collaborators of K. Peter Hirth. A scholar is included among the top collaborators of K. Peter Hirth based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K. Peter Hirth. K. Peter Hirth is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | Inhibition of angiogenesis decreases alveolarization in the developing rat lung breakdown → | 513 |
| 3 | 67 | |
| 4 | 18 | |
| 5 | SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. | 402 |
| 6 | 129 | |
| 7 | SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. breakdown → | 885 |
| 8 | Inhibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N-[4-(trifluoromethyl)-phenyl]5-methylisoxazole-4-carboxamide. | 112 |
| 9 | 4 | |
| 10 | 26 | |
| 11 | 9 | |
| 12 | 40 | |
| 13 | 38 | |
| 14 | 21 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.